Allogeneic stem cell transplantation in patients with non-Hodgkin lymphoma who experienced relapse or progression after autologous stem cell transplantation

Ji Won Kim, Byung Su Kim, Soo Mee Bang, Inho Kim, Dong Hwan Kim, Won Seog Kim, Deok Hwan Yang, Je Jung Lee, Je Hwan Lee, Jinseok Kim, Sang Kyun Sohn, Ho Young Yhim, Jae Yong Kwak, Sung Soo Yoon, Jong Seok Lee, Seonyang Park, Byoung Kook Kim

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

There are few treatment options for patients with non-Hodgkin lymphoma (NHL) who experienced progression after high-dose chemotherapy (HDC) with autologous stem cell transplantation (auto-SCT). The role of allogeneic stem cell transplantation (allo-SCT) in these patients has not been clarified yet. In this study, we report clinical outcomes of allo-SCT in patients with NHL who experienced progression after HDC with auto-SCT. Patients were enrolled from seven hospitals in Korea. A total of 38 patients were included: 18 patients (47.4%) underwent myeloablative conditioning and 20 patients (52.6%) reduced intensity conditioning. Overall response rate was 73.3%. Median event-free survival was 6.3 months. Median overall survival (OS) was 19.0 months. Estimated 5-year survival rate was 35.0%. Acute graft-versus-host disease developed in 13 patients (34.2%). Transplant-related mortality (TRM) was 21.1% (eight patients). Ann Arbor stage (p = 0.022), performance status (p < 0.001), and baseline serum albumin level (p = 0.010) were significant risk factors for OS. Performance status (p = 0.022) was a significant risk factor for TRM. Eight patients with persistent or progressive disease received donor lymphocyte infusion, and two of them achieved complete remission. In conclusion, despite high TRM, allo-SCT is a viable option for patients with NHL who underwent progression after HDC with auto-SCT.

Original languageEnglish
Pages (from-to)1409-1418
Number of pages10
JournalAnnals of Hematology
Volume90
Issue number12
DOIs
Publication statusPublished - 2011 Dec 1

Fingerprint

Stem Cell Transplantation
Non-Hodgkin's Lymphoma
Recurrence
Transplants
Drug Therapy
Mortality
Survival
Graft vs Host Disease
Korea
Serum Albumin
Disease-Free Survival
Survival Rate
Tissue Donors
Lymphocytes

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Kim, Ji Won ; Kim, Byung Su ; Bang, Soo Mee ; Kim, Inho ; Kim, Dong Hwan ; Kim, Won Seog ; Yang, Deok Hwan ; Lee, Je Jung ; Lee, Je Hwan ; Kim, Jinseok ; Sohn, Sang Kyun ; Yhim, Ho Young ; Kwak, Jae Yong ; Yoon, Sung Soo ; Lee, Jong Seok ; Park, Seonyang ; Kim, Byoung Kook. / Allogeneic stem cell transplantation in patients with non-Hodgkin lymphoma who experienced relapse or progression after autologous stem cell transplantation. In: Annals of Hematology. 2011 ; Vol. 90, No. 12. pp. 1409-1418.
@article{d5d91899c2424851b1f9c44de8ff2d45,
title = "Allogeneic stem cell transplantation in patients with non-Hodgkin lymphoma who experienced relapse or progression after autologous stem cell transplantation",
abstract = "There are few treatment options for patients with non-Hodgkin lymphoma (NHL) who experienced progression after high-dose chemotherapy (HDC) with autologous stem cell transplantation (auto-SCT). The role of allogeneic stem cell transplantation (allo-SCT) in these patients has not been clarified yet. In this study, we report clinical outcomes of allo-SCT in patients with NHL who experienced progression after HDC with auto-SCT. Patients were enrolled from seven hospitals in Korea. A total of 38 patients were included: 18 patients (47.4{\%}) underwent myeloablative conditioning and 20 patients (52.6{\%}) reduced intensity conditioning. Overall response rate was 73.3{\%}. Median event-free survival was 6.3 months. Median overall survival (OS) was 19.0 months. Estimated 5-year survival rate was 35.0{\%}. Acute graft-versus-host disease developed in 13 patients (34.2{\%}). Transplant-related mortality (TRM) was 21.1{\%} (eight patients). Ann Arbor stage (p = 0.022), performance status (p < 0.001), and baseline serum albumin level (p = 0.010) were significant risk factors for OS. Performance status (p = 0.022) was a significant risk factor for TRM. Eight patients with persistent or progressive disease received donor lymphocyte infusion, and two of them achieved complete remission. In conclusion, despite high TRM, allo-SCT is a viable option for patients with NHL who underwent progression after HDC with auto-SCT.",
author = "Kim, {Ji Won} and Kim, {Byung Su} and Bang, {Soo Mee} and Inho Kim and Kim, {Dong Hwan} and Kim, {Won Seog} and Yang, {Deok Hwan} and Lee, {Je Jung} and Lee, {Je Hwan} and Jinseok Kim and Sohn, {Sang Kyun} and Yhim, {Ho Young} and Kwak, {Jae Yong} and Yoon, {Sung Soo} and Lee, {Jong Seok} and Seonyang Park and Kim, {Byoung Kook}",
year = "2011",
month = "12",
day = "1",
doi = "10.1007/s00277-011-1227-y",
language = "English",
volume = "90",
pages = "1409--1418",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "12",

}

Kim, JW, Kim, BS, Bang, SM, Kim, I, Kim, DH, Kim, WS, Yang, DH, Lee, JJ, Lee, JH, Kim, J, Sohn, SK, Yhim, HY, Kwak, JY, Yoon, SS, Lee, JS, Park, S & Kim, BK 2011, 'Allogeneic stem cell transplantation in patients with non-Hodgkin lymphoma who experienced relapse or progression after autologous stem cell transplantation', Annals of Hematology, vol. 90, no. 12, pp. 1409-1418. https://doi.org/10.1007/s00277-011-1227-y

Allogeneic stem cell transplantation in patients with non-Hodgkin lymphoma who experienced relapse or progression after autologous stem cell transplantation. / Kim, Ji Won; Kim, Byung Su; Bang, Soo Mee; Kim, Inho; Kim, Dong Hwan; Kim, Won Seog; Yang, Deok Hwan; Lee, Je Jung; Lee, Je Hwan; Kim, Jinseok; Sohn, Sang Kyun; Yhim, Ho Young; Kwak, Jae Yong; Yoon, Sung Soo; Lee, Jong Seok; Park, Seonyang; Kim, Byoung Kook.

In: Annals of Hematology, Vol. 90, No. 12, 01.12.2011, p. 1409-1418.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Allogeneic stem cell transplantation in patients with non-Hodgkin lymphoma who experienced relapse or progression after autologous stem cell transplantation

AU - Kim, Ji Won

AU - Kim, Byung Su

AU - Bang, Soo Mee

AU - Kim, Inho

AU - Kim, Dong Hwan

AU - Kim, Won Seog

AU - Yang, Deok Hwan

AU - Lee, Je Jung

AU - Lee, Je Hwan

AU - Kim, Jinseok

AU - Sohn, Sang Kyun

AU - Yhim, Ho Young

AU - Kwak, Jae Yong

AU - Yoon, Sung Soo

AU - Lee, Jong Seok

AU - Park, Seonyang

AU - Kim, Byoung Kook

PY - 2011/12/1

Y1 - 2011/12/1

N2 - There are few treatment options for patients with non-Hodgkin lymphoma (NHL) who experienced progression after high-dose chemotherapy (HDC) with autologous stem cell transplantation (auto-SCT). The role of allogeneic stem cell transplantation (allo-SCT) in these patients has not been clarified yet. In this study, we report clinical outcomes of allo-SCT in patients with NHL who experienced progression after HDC with auto-SCT. Patients were enrolled from seven hospitals in Korea. A total of 38 patients were included: 18 patients (47.4%) underwent myeloablative conditioning and 20 patients (52.6%) reduced intensity conditioning. Overall response rate was 73.3%. Median event-free survival was 6.3 months. Median overall survival (OS) was 19.0 months. Estimated 5-year survival rate was 35.0%. Acute graft-versus-host disease developed in 13 patients (34.2%). Transplant-related mortality (TRM) was 21.1% (eight patients). Ann Arbor stage (p = 0.022), performance status (p < 0.001), and baseline serum albumin level (p = 0.010) were significant risk factors for OS. Performance status (p = 0.022) was a significant risk factor for TRM. Eight patients with persistent or progressive disease received donor lymphocyte infusion, and two of them achieved complete remission. In conclusion, despite high TRM, allo-SCT is a viable option for patients with NHL who underwent progression after HDC with auto-SCT.

AB - There are few treatment options for patients with non-Hodgkin lymphoma (NHL) who experienced progression after high-dose chemotherapy (HDC) with autologous stem cell transplantation (auto-SCT). The role of allogeneic stem cell transplantation (allo-SCT) in these patients has not been clarified yet. In this study, we report clinical outcomes of allo-SCT in patients with NHL who experienced progression after HDC with auto-SCT. Patients were enrolled from seven hospitals in Korea. A total of 38 patients were included: 18 patients (47.4%) underwent myeloablative conditioning and 20 patients (52.6%) reduced intensity conditioning. Overall response rate was 73.3%. Median event-free survival was 6.3 months. Median overall survival (OS) was 19.0 months. Estimated 5-year survival rate was 35.0%. Acute graft-versus-host disease developed in 13 patients (34.2%). Transplant-related mortality (TRM) was 21.1% (eight patients). Ann Arbor stage (p = 0.022), performance status (p < 0.001), and baseline serum albumin level (p = 0.010) were significant risk factors for OS. Performance status (p = 0.022) was a significant risk factor for TRM. Eight patients with persistent or progressive disease received donor lymphocyte infusion, and two of them achieved complete remission. In conclusion, despite high TRM, allo-SCT is a viable option for patients with NHL who underwent progression after HDC with auto-SCT.

UR - http://www.scopus.com/inward/record.url?scp=84355161831&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84355161831&partnerID=8YFLogxK

U2 - 10.1007/s00277-011-1227-y

DO - 10.1007/s00277-011-1227-y

M3 - Article

C2 - 21468694

AN - SCOPUS:84355161831

VL - 90

SP - 1409

EP - 1418

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 12

ER -